Vetoquinol (PA:VETO) — Market Cap & Net Worth
Market Cap & Net Worth: Vetoquinol (VETO)
Vetoquinol (PA:VETO) has a market capitalization of $1.00 Billion (€856.64 Million) as of May 23, 2026. Listed on the PA stock exchange, this France-based company holds position #9162 globally and #145 in its home market, demonstrating a 2.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vetoquinol's stock price €72.60 by its total outstanding shares 11799419 (11.80 Million). Analyse cash efficiency ratio of Vetoquinol to see how efficiently the company converts income to cash.
Vetoquinol Market Cap History: 2015 to 2026
Vetoquinol's market capitalization history from 2015 to 2026. Data shows growth from $505.00 Million to $1.00 Billion (6.34% CAGR).
Index Memberships
Vetoquinol is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Health Care
FRHC
|
$257.15 Billion | 0.39% | #12 of 36 |
Weight: Vetoquinol's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vetoquinol Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vetoquinol's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.92x
Vetoquinol's market cap is 1.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.61x
Vetoquinol's market cap is 17.61 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $505.00 Million | $342.61 Million | $24.16 Million | 1.47x | 20.91x |
| 2016 | $590.26 Million | $350.35 Million | $27.83 Million | 1.68x | 21.21x |
| 2017 | $791.39 Million | $352.17 Million | $34.83 Million | 2.25x | 22.72x |
| 2018 | $670.20 Million | $367.94 Million | $36.26 Million | 1.82x | 18.48x |
| 2019 | $857.45 Million | $395.99 Million | $28.59 Million | 2.17x | 29.99x |
| 2020 | $1.12 Billion | $427.47 Million | $19.22 Million | 2.62x | 58.29x |
| 2021 | $1.78 Billion | $521.27 Million | $62.86 Million | 3.41x | 28.28x |
| 2022 | $1.19 Billion | $539.78 Million | $47.99 Million | 2.20x | 24.74x |
| 2023 | $1.40 Billion | $529.27 Million | $55.56 Million | 2.65x | 25.22x |
| 2024 | $1.03 Billion | $539.20 Million | $58.69 Million | 1.92x | 17.61x |
Competitor Companies of VETO by Market Capitalization
Companies near Vetoquinol in the global market cap rankings as of May 23, 2026.
Key companies related to Vetoquinol by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #500 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #550 globally with a market cap of $48.03 Billion USD ( CN¥328.20 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $47.66 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #612 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #500 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #550 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.03 Billion | CN¥51.45 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $47.66 Billion | $40.64 |
| #612 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.00 |
Vetoquinol Historical Marketcap From 2015 to 2026
Between 2015 and today, Vetoquinol's market cap moved from $505.00 Million to $ 1.00 Billion, with a yearly change of 6.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.00 Billion | -13.05% |
| 2025 | €1.15 Billion | +11.48% |
| 2024 | €1.03 Billion | -26.25% |
| 2023 | €1.40 Billion | +17.97% |
| 2022 | €1.19 Billion | -33.18% |
| 2021 | €1.78 Billion | +58.63% |
| 2020 | €1.12 Billion | +30.68% |
| 2019 | €857.45 Million | +27.94% |
| 2018 | €670.20 Million | -15.31% |
| 2017 | €791.39 Million | +34.08% |
| 2016 | €590.26 Million | +16.88% |
| 2015 | €505.00 Million | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of Vetoquinol was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Billion USD |
| MoneyControl | $1.00 Billion USD |
| MarketWatch | $1.00 Billion USD |
| marketcap.company | $1.00 Billion USD |
| Reuters | $1.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more